GSK

Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: JNJ, ABT, LLY, PFE, NVS, GSK

DALLAS, Feb. 18 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://www.BeaconEquity.com/m Today's Trade Alerts include: Johnson & Johnson (NYSE: ...

Eurand and GSK Reach Development Milestone

Eurand N.V., a global specialty pharmaceutical company, announced today that Eurand, Inc. and its collaboration partner, GlaxoSmithKline (NYSE: GSK), reached a significant milestone in the development of an orally disintegrating tablet formulation of an undisclosed compound. GSK has starte...

Valeant Pharmaceuticals Reports Second Quarter Financial Results

...n and $25.8 million, alliance revenue from the gsk collaboration of $2.8 million and $6.1 million and... Three months ended gsk Collaboration - Retagibine ... 5,533 gsk incurred cost ...

Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments

...sitive Results On July 20, 2009, HGS and gsk announced that BENLYSTA (belimumab) met the primar... 50 years. BENLYSTA is being developed by HGS and gsk under a co-development and commercialization agree...n Type 2 Diabetes Patients In June 2009, gsk announced that new Phase 2 data presented at the A...

GSK - Improving Performance to Continue in Second Half

... LONDON, July 22 /PRNewswire-FirstCall/ -- gsk announced its sales and turnover fell by less than expected in Q2. The Phar... about the improving outlook for the second half of the year, Andrew Witty, gsk Chief Executive, said: "As we go into the second half of the year I expect ...

GSK to Announce Q2 Results July 22, 2009

...ewswire-FirstCall/ -- On Wednesday, July 22nd, GlaxoSmithKline plc (NYSE: gsk ) will announce its second quarter financial results for the three months e... US Toll Free Phone + 1 866 804 8688 Please quote: gsk Second Quarter Results At approximately 4:00 pm EDT the webcast ...

Mahindra Satyam Signs 5 Year SAP Contract with GlaxoSmithKline

... support to GSK's businesses across the world. Satyam has been working with gsk since 2002 to provide IT application development and support services. ...on our way to regain our position as a market leader and we are thankful to gsk for having reposed their faith in us." About Mahindra Satyam Ma...

GlaxoSmithKline Opens $600million Vaccine Plant In Singapore

...-art vaccine plant to hire 200 staff in Singapore, gsk and the Singapore Economic Development Board (EDB)...ort to develop talent and leadership in Singapore, gsk is setting up a $30 million endowment fund here to...t Biopolis. In addition to this new vaccine plant, gsk has two global manufacturing and supply sites loca...

Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)

...t candidate for the treatment of obesity. "This license agreement with gsk complements the IP foundation of Contrave, providing us with additional pro...ommercialize Contrave and the expected impact of the license agreement with gsk on Orexigen's financial position. The inclusion of forward-looking stateme...

Avandia Attorney Says Study Based on 'Useless Trick Science'

...Lanier Law Firm says "useless trick science" is the basis for a new study being unveiled today in New Orleans by drug maker GlaxoSmithKline (NYSE: gsk ) about the side effects caused by the company's diabetes medication Avandia , which reportedly has been linked to heart problems in thousands of p...

More>>

GSK in Medical Technology

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years

New study results also show evidence of additional protection against infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- The GlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R), demonstrated 100 percent efficacy in preventing precancero...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing Virus Types 16 & 18 That Are At Least Ten Times Greater Than Natural Infection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data show that at 18 months after the first of a three-dose regimen, 100 percent of women up to ag...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...cluding the $500,000 discovery milestone payment that Regulus received from gsk for demonstrating a pharmacological effect in immune cells by specific micr...efforts to build its team to support its internal microRNA programs and its gsk collaboration. Regulus generated a loss from operations, excluding non-cas...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... from our second Phase 3 trial of BENLYSTA, we and gsk plan to submit marketing applications in the Unite...50 years. Belimumab is being developed by HGS and gsk under a co-development and commercialization agree...hase 3 program for belimumab in collaboration with gsk and leading international SLE experts, and the pro...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

...obal Clinical R&D and Chief Medical Officer of gsk Biologicals commented: "These excellent study resu...l countries including Japan and the United States. gsk also submitted the vaccine to the World Health Org...screening. GlaxoSmithKline Biologicals -- gsk Biologicals, GlaxoSmithKline's vaccines business, ...

FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight

...rietary albumin-fusion technology, and licensed to gsk in 2004. HGS is entitled to fees and milestone pa...Syncria is commercialized. In February 2009, gsk announced initiation of a Phase 3 clinical trial p...cted to the contacts provided by GSK. To view the gsk press release, please click here . For mor...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

...ionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, gsk cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

...onary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, gsk cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...loped under a collaboration between Genmab and the gsk Oncology and BioPharm R&D Units. Ofatumum..., visit GlaxoSmithKline at www.gsk.com . gsk Oncology is dedicated to producing innovations in... collaborations with more than 160 cancer centers. gsk is closing in on cancer from all sides with a new ...

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)

...and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the gsk clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglut...

GSK in Biological News

South African Tribunal Asks For Damages Estimates in GSK AIDS Drug Case

A landmark South African legal complaint against British drug maker GlaxoSmithKline (GSK) over its AIDS drug pricing and policies in that country will proceed following an order late last week by South Africa's Competition Tribunal that will allow the complaint to go forward. GSK has sought outrigh...

DNA barcoding of mosquito species deployed in bid to end elephantiasis

...ing people at risk with annual doses of a combination drug therapy (albendazole / DEC or albendazole / ivermectin, freely donated by Merck and Co. and gsk respectively). The drug reduces the density of worm larvae in humans. This LF elimination strategy relies on a belief that the region's main LF ve...

International public-private partnership offers new paradigm for medicinal chemistry

...ent of Drug Discovery at GSK. "This link between the academic community and gsk in an emerging area of science should enhance knowledge and ultimately supp...ntist at SGC in Oxford. "I believe this venture creates a paradigm shift as gsk opens up its internal chemistry capability to create new chemical probes th...

A new weapon in the fight against obesity and diabetes

...vity and enhances exercise endurance by enhancing fat utilization in certain target tissues. The new chemical entity was developed by Sirtris, a a gsk company, and the research study was led by EPFL professor Johan Auwerx, MD. Reducing calorie consumption by about 20% has been shown to slow down t...

Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery

... CAMBRIDGE, MA [October 1, 2008] Sirtris, a gsk company focused on discovering and developing small molecule drugs to treat...said Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, a gsk company. "The body of clinical data supporting the role of SIRT1 activati...

Long-term study of middle-aged mice shows

...als and DNA damage. "Frailty in humans is an important health concern," says Christoph Westphal, M.D., Ph.D., Chief Executive Officer, Sirtris, a gsk Company. "This study informs us how frailty in mice can be delayed, and this knowledge could help us translate preclinical benefits to humans. We are ...

GSK in Biological Technology

Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate

PALO ALTO, Calif., Jan. 12 /PRNewswire/ -- Anacor Pharmaceuticals today announced that it has achieved its first candidate selection milestone payment of $3 million from its collaboration partner, GlaxoSmithKline. Anacor may receive future milestone payments and royalties should this product ...

Gilead to Topple GSK as the Top Player in the Anti-Infectives Drug Market in 2014

Stringent, Yet Ill-Defined, Approval Standards Make it Difficult for Companies to Bring Hospital Antibiotics to Market, According to a New Report from Decision Resources WALTHAM, Mass., Nov. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusin...

Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK

COPENHAGEN, Denmark, July 28 /PRNewswire/ -- Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline. The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chem...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... sales momentum from our co-promote agreement with gsk for adult ADHD. We are also expecting further posi... treatment of ADHD - On May 1, 2009 Shire and gsk commenced working together on the co-promoti...tion and AIDS Shire receives royalties from gsk on worldwide sales of 3TC(R) sales. Royalties from...

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

...onary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, gsk cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and...

GlaxoSmithKline Completes Acquisition of Stiefel

...e-FirstCall/ -- GlaxoSmithKline plc (GSK) (NYSE: gsk ) today announced that it has completed its acquisition of Stiefel Laboratories, Inc. gsk has acquired the total share capital of Stiefel for a cash consideration of $2.9 billion. gsk also assumed $0.4 billion of net debt. Under the ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

...and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the gsk clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglut...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

...t GlaxoSmithKline will have an exclusive option to license each compound for further development and commercialisation on a worldwide basis. Presently gsk has selected one viral disease target and Santaris Pharma has identified several strong drug candidates against the target. Enzon Collaboration...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

...and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the gsk clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglut...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...-76 Novacea Licenses Asenstar Prostate Cancer Drug to Schering-Plough II-76 Bentley Receives Approval for Generic Version of Casodex II-76 gsk Acquires Praecis Pharmaceuticals II-77 Samaritan Acquires Metastatin Pharma II-77 Champions Biotechnology Acquires Patent Rights for Potential...